Prediction of bioactivities of microsomal prostaglandin E2 synthase-1 inhibitors by machine learning algorithms

被引:1
|
作者
Tian, Yujia [1 ]
Yang, Zhenwu [1 ]
Wang, Hongzhao [1 ]
Yan, Aixia [1 ,2 ]
机构
[1] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, Beijing, Peoples R China
[2] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, POB 53, 15 BeiSanHuan East Rd, Beijing 100029, Peoples R China
关键词
applicability domain (AD); machine learning (ML); microsomal prostaglandin E-2 synthase-1 (mPGES-1) inhibitor; quantitative structure-activity relationship (QSAR); self-attention recurrent neural networks (RNN); APPLICABILITY DOMAIN; QSAR; IDENTIFICATION; CHALLENGES; REGRESSION; DISCOVERY; DESIGN; TARGET;
D O I
10.1111/cbdd.14214
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is a strong interest in the development of microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors of their potential to safely and effectively treat inflammation. Herein, 70 QSAR models were built on the dataset (735 mPGES-1 inhibitors) characterized with RDKit descriptors by multiple linear regression (MLR), support vector machine (SVM), random forest (RF), deep neural networks (DNN), and eXtreme Gradient Boosting (XGBoost). The other three regression models on the dataset are represented by SMILES using self-attention recurrent neural networks (RNN) and Graph Convolutional Networks (GCN). For the best model (Model C2), which was developed by SVM with RDKit descriptors, the coefficient of determination (R-2) of 0.861 and root mean squared error (RMSE) of 0.235 were achieved for the test set. Additionally, R-2 of 0.692 and RMSE of 0.383 were obtained on the external test set. We investigated the applicability domain (AD) of Model C2 with the rivality index (RI), the prediction of Model C2 on 78.92% of molecules in the test set, and 78.33% of molecules in the external test set were reliable. After dissecting the RDKit descriptors of Model C2, we found important physicochemical properties of highly active mPGES-1 inhibitors. Besides, by analyzing the attention weight of each atom of each inhibitor from the attention layer, we found that the benzamide group and the trifluoromethyl cyclohexane group are favorable substructures for mPGES-1 inhibitors.
引用
收藏
页码:1307 / 1321
页数:15
相关论文
共 50 条
  • [31] Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase
    Ergul, Azize Gizem
    Maz, Tugce Gur
    Kretzer, Christian
    Olgac, Abdurrahman
    Jordan, Paul M.
    Caliskan, Burcu
    Werz, Oliver
    Banoglu, Erden
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 231
  • [32] Aminothiazole-Featured Pirinixic Acid Derivatives As Dual 5-Lipoxygenase and Microsomal Prostaglandin E2 Synthase-1 Inhibitors with Improved Potency and Efficiency in Vivo
    Hanke, Thomas
    Dehm, Friederike
    Liening, Stefanie
    Popella, Sven-Desiderius
    Maczewsky, Jonas
    Pillong, Max
    Kunze, Jens
    Weinigel, Christina
    Barz, Dagmar
    Kaiser, Astrid
    Wurglics, Mario
    Laemmerhofer, Michael
    Schneider, Gisbert
    Sautebin, Lidia
    Schubert-Zsilavecz, Manfred
    Werz, Oliver
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (22) : 9031 - 9044
  • [33] Virtual screening, molecular simulations and bioassays: Discovering novel microsomal prostaglandin E Synthase-1 (mPGES-1) inhibitors
    Babaoglu, Zeynep Yagmur
    Kilic, Deryanur
    COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 155
  • [34] Molecular Docking and Competitive Binding Study Discovered Different Binding Modes of Microsomal Prostaglandin E Synthase-1 Inhibitors
    He, Shan
    Lai, Luhua
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2011, 51 (12) : 3254 - 3261
  • [35] Discovery and optimization of pyridyl-cycloalkyl-carboxylic acids as inhibitors of microsomal prostaglandin E synthase-1 for the treatment of endometriosis
    Koppitz, Marcus
    Braeuer, Nico
    Ter Laak, Antonius
    Irlbacher, Horst
    Rotgeri, Andrea
    Coelho, Anne-Marie
    Walter, Daryl
    Steinmeyer, Andreas
    Zollner, Thomas M.
    Peters, Michaele
    Nagel, Jens
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (18) : 2700 - 2705
  • [36] Insights on Microsomal Prostaglandin E2 Synthase 1 (mPGES-1) Inhibitors using Molecular Dynamics and MM/PBSA Calculations
    dos Santos Nascimento, Igor Jose
    de Aquino, Thiago Mendonca
    da Silva Junior, Edeildo Ferreira
    de Moura, Ricardo Olimpio
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (06) : 1033 - 1047
  • [37] Microsomal Prostaglandin E Synthase-1 Deficiency Exacerbates Pulmonary Fibrosis Induced by Bleomycin in Mice
    Wei, Bo
    Cai, Linhong
    Sun, Dan
    Wang, Yanhua
    Wang, Cairui
    Chai, Xiaoyu
    Xie, Feng
    Su, Ming
    Ding, Fangrui
    Liu, Jie
    Yang, Jichun
    Guan, Youfei
    Liu, Xinmin
    MOLECULES, 2014, 19 (04): : 4967 - 4985
  • [38] Microsomal Prostaglandin E Synthase-1 and-2: Emerging Targets in Non-Alcoholic Fatty Liver Disease
    Kotsos, Dimitrios
    Tziomalos, Konstantinos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [39] Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors
    Kuklish, Steven L.
    Antonysamy, Stephen
    Bhattachar, Shobha N.
    Chandrasekhar, Srinivasan
    Fisher, Matthew J.
    Fretland, Adrian J.
    Gooding, Karen
    Harvey, Anita
    Hughes, Norman E.
    Luz, John G.
    Manninen, Peter R.
    Mcgee, James E.
    Navarro, Antonio
    Norman, Bryan H.
    Partridge, Katherine M.
    Quimby, Steven J.
    Schiffler, Matthew A.
    Sloan, Ashley V.
    Warshawsky, Alan M.
    York, Jeremy S.
    Yu, Xiao-Peng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (19) : 4824 - 4828
  • [40] A Facilitated Approach to Evaluate the Inhibitor Mode and Potency of Compounds Targeting Microsomal Prostaglandin E Synthase-1
    Spahiu, Linda
    Stenberg, Patric
    Larsson, Charlotte
    Wannberg, Johan
    Alterman, Mathias
    Kull, Bjorn
    Nekhotiaeva, Natalia
    Morgenstern, Ralf
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2011, 9 (05) : 487 - 495